Role of the Cardiophrenic Lymph Node Status After Neoadjuvant Chemotherapy in Primary Advanced Ovarian Cancer

Anticancer Res. 2021 Oct;41(10):5025-5031. doi: 10.21873/anticanres.15317.

Abstract

Background/aim: This study investigated the cardiophrenic lymph node (CPLN) status before and after neoadjuvant chemotherapy (NACT), as its presence seems to have a rather prognostic significance in patients with advanced ovarian cancer.

Patients and methods: The baseline computed tomography scans of 66 patients with advanced ovarian cancer primary treated with NACT between March 2015 and June 2020 were reviewed. A CPLN enlargement was defined as ≥5 mm.

Results: 44% (n=29) of the patients had enlarged CPLNs; 10.7% (n=3) showed a complete response, 71.4% (n=20) a partial response, and 17.9% (n=5) a stable disease after NACT. There was no significant difference between the response to NACT measured according to the status of CPLN compared to other biomarkers in the CPLN group.

Conclusion: Patients with CPLN enlargement have a tendency to an impaired prognosis. The response of CPLN to NACT was comparable to the response of established biomarkers, adding a monitoring function to the CPLN.

Keywords: Ovarian neoplasms; computed tomography; lymphatic metastasis; neoadjuvant therapy.

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chemotherapy, Adjuvant / mortality*
  • Diaphragm
  • Female
  • Follow-Up Studies
  • Humans
  • Lymph Nodes / drug effects
  • Lymph Nodes / pathology*
  • Middle Aged
  • Neoadjuvant Therapy / mortality*
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / pathology*
  • Prognosis
  • Retrospective Studies
  • Survival Rate